Xencor | XNCR - Equity Capital And Reserves


Xencor reported $503.23M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -5.94B 721M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
Arrowhead Research USD 465.53M 148.45M Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Cytokinetics USD -173.49M 653.08M Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
J&J USD 84.97B 3.78B Jun/2026
Karyopharm Therapeutics USD -265.65M 27.28M Mar/2026
MacroGenics USD 21.2M 34.39M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Novartis USD 41.95B 3.02B Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Xencor USD 503.23M 12.4M Jun/2026